In addition to CRC, studies have demonstrated that solid tumors of multiple tissue types exhibiting MSI show durable response to PD‐L1 blockade, and based on this evidence, the FDA approved these agents for use in any cancers that histologically exhibit MSI (Lemery et al., 2017). This evidence concerns the gene CD274 and colorectal carcinoma.